Abstract:Regulatory T cells (Tregs) in peripheral blood and tumor infiltrating lymphocytes (TILs) play crucial roles in suppressing anti-tumor immune responses in cancer patients, and correlate with clinical outcomes. We identified an important subpopulation, CD13(+)CD4(+)CD25(hi)Treg cells, among CD4(+)CD25(hi)Treg cells in the peripheral blood of non-small cell lung cancer (NSCLC) patients. Peripheral blood mononuclear cells (PBMCs) were isolated from patients with NSCLC (n = 72) or from healthy donors (n = 30). Flow cytometric analyses were performed to study the expression of cell-surface or intracellular markers on the CD4(+)CD25(hi)Treg cells. The immune suppressive function of CD13(+)CD4(+)CD25(hi)Treg cells was evaluated by co-culturing with CD4(+)CD25(-)T cells that were activated by PHA. Our data showed that, compared with CD4(+)CD25(Low/-)T cells, CD13 expression was enriched on CD4(+)CD25(hi)Treg cells. The CD13(+)CD4(+)CD25(hi)Treg cells also expressed higher levels of Foxp3, CTLA-4, membrane-bound transforming growth factor beta 1 (mTGF beta 1) and B7-H1, and are more suppressive to CD25 expression and proliferation of CD4(+)CD25(-)T cells. Additionally, we showed that the expression of Foxp3, CTLA-4, B7-H1, mTGF beta 1 and the secretion of TGF beta 1 and IL-10 on CD13(+)CD4(+)CD25(hi)Treg cells was significantly suppressed by anti-CD13 mAb (WM15), and the ability of these cells to suppress CD25 expression and proliferation of CD4(+)CD25(-)T cells was inhibited by WM15 as well. Interestingly, the percentage of CD13(+)CD4(+)CD25(hi)Treg cells among the CD4(+)CD25(hi)Treg population increased significantly and correlated with pathological stage in NSCLC: healthy donor (9.84% +/- 2.23%) <stage I (21.64% +/- 2.78%) <stage II (31.86% +/- 3.01%) <stage III (45.64% +/- 6.12%) <stage IV (58.78% +/- 12.89%). Moreover, the percentage of CD13(+)CD4(+)CD25(hi)Treg cells decreased dramatically after surgical removal of tumors. CD13 is a new surface molecule for identifying a CD4(+)CD25(hi)Treg cell subpopulation with higher suppressive ability. The percentage of CD13(+)CD4(+)CD25(hi)Treg cells among the CD4(+)CD25(hi)Treg cell population correlated with the pathological stage in NSCLC and tumor burden. CD13 represents a potential target to suppress Treg cells in anti-tumor therapy.

CD4~+ CD25~+-regulatory T cells in peripheral blood from patients with non small cell lung carcinoma

INVESTIGATION OF REGULATORY T CELLS IN PATIENTS WITH NON-SMALL CELL LUNG CANCER

Expression and significance of CD4+CD25high regulatory T cells in patients with non-small-cell lung cancer

Expression of regulatory T cells in the peripheral blood and its clinical significance in patients with non-small cell lung cancer

Clinical significance of regulatory T cell in peripheral blood in patients with lung cancer

CD13+CD4+CD25hiregulatory T Cells Exhibit Higher Suppressive Function and Increase with Tumor Stage in Non-Small Cell Lung Cancer Patients

Distribution of Peripheral Blood T Helper 17 Cells and IL-17+FoxP3+T Cells in Patients with Non-Small-cell Lung Cancer

Detection of T Lymphocyte Subsets in the Peripheral Blood of Patients with Advanced Lung Adenocarcinoma

The difference of CD4+CD25+ regulatory T cells and Foxp3 expression in non-small cell lung cancer patients with different lymph node metastasis status

Analysis of NK/T and Treg cell in peripheral blood of patients with different malignancies during the chemotherapy

[Quantitative Studies on Expression of Peripheral Blood CD44 and CD54 in Non-Small Cell Lung Carcinoma].

The variation of CD4 + CD25 + regulatory T cells in the periphery blood and tumor microenvironment of non-small cell lung cancer patients and the downregulation effects induced by CpG ODN

Analysis on the Change of Peripheral Blood T Lymphocyte Subsets Before and after Chemotherapy in Patients with Non-Small Cell Lung Cancer

T lymphocyte subsets and PD-1 expression on lymphocytes in peripheral blood of patients with non-small cell lung cancer

Prognostic significance of peripheral and tumor-infiltrating lymphocytes in newly diagnosed stage III/IV non-small-cell lung cancer

Circulating activated immune cells as a potential blood biomarkers of non-small cell lung cancer occurrence and progression

Circulating Tumor Cells Were Associated with the Number of T Lymphocyte Subsets and NK Cells in Peripheral Blood in Advanced Non-Small-Cell Lung Cancer

Study on the subset of T lymphocyte and CD4 + CD25 + regulatory cells in peripheral blood in patients with gastric cancer

Prognostic Significance of Tumor-infiltrating CD8+ or CD3+ T Lymphocytes and Interleukin-2 Expression in Radically Resected Non-small Cell Lung Cancer

Tumor-Associated Regulatory T Cells in Non-Small-Cell Lung Cancer: Current Advances and Future Perspectives

Modified spatial architecture of regulatory T cells after neoadjuvant chemotherapy in non-small cell lung cancer patients